2002
Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. Journal Of Clinical Oncology 2002, 20: 4440-7. PMID: 12431966, DOI: 10.1200/jco.2002.04.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntibiotics, AntineoplasticAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCyclohexanesDrug Administration ScheduleFemaleHumansLung NeoplasmsMaleMiddle AgedO-(Chloroacetylcarbamoyl)fumagillolPaclitaxelSesquiterpenesTreatment OutcomeConceptsTNP-470Solid tumorsPharmacokinetic interactionsOptimal doseAntiangiogenic agent TNP-470Minimal pharmacokinetic interactionsNeuropsychiatric test resultsSingle-agent doseMaximum-tolerated doseDoses of paclitaxelCell lung cancerPaclitaxel dosePrior chemotherapyChemotherapy regimensCombination regimenMedian survivalPartial responseArm AArm BPaclitaxel clearanceTreatment armsCytotoxic therapyLung cancerPharmacokinetic effectsPreclinical studiesAngiogenesis as a target for cancer therapy
Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematology/Oncology Clinics Of North America 2002, 16: 1125-1171. PMID: 12512387, DOI: 10.1016/s0889-8588(02)00047-3.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAngiostatinsAnimalsAntibodies, MonoclonalAnticarcinogenic AgentsCell HypoxiaChildClinical Trials as TopicCollagenCyclooxygenase InhibitorsDrug DesignEndostatinsEndothelium, VascularEphrinsGrowth SubstancesHumansImmunotherapyIntegrin alphaVbeta3LigasesMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMiceNeoplasm ProteinsNeoplasmsNeovascularization, PathologicOutcome Assessment, Health CarePeptide FragmentsPlasminogenProtease InhibitorsReceptors, Eph FamilyReceptors, Growth FactorThrombospondinsTumor Suppressor ProteinsUbiquitin-Protein LigasesVon Hippel-Lindau Tumor Suppressor ProteinAngiogenesis inhibitors in lung cancer
Kim ES, Herbst RS. Angiogenesis inhibitors in lung cancer. Current Oncology Reports 2002, 4: 325-333. PMID: 12044242, DOI: 10.1007/s11912-002-0008-0.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAngiostatinsCarcinoma, Non-Small-Cell LungCollagenCyclohexanesEndostatinsHumansLung NeoplasmsO-(Chloroacetylcarbamoyl)fumagillolPeptide FragmentsPlasminogenReceptor Protein-Tyrosine KinasesReceptors, Growth FactorReceptors, Vascular Endothelial Growth FactorSesquiterpenesSurvival RateThalidomideConceptsLung cancerAngiogenesis inhibitorsSurvival rateMajor public health problemVascular endothelial growth factor receptorOngoing randomized studiesCell lung cancerEndothelial growth factor receptorTraditional cytotoxic therapiesCancer-related deathImproved survival ratesPublic health problemSevere side effectsInhibitors of angiogenesisEndogenous angiogenesis inhibitorGrowth factor receptorMetastatic diseaseRandomized studyChemotherapy dosesClinical benefitCytotoxic therapyCyclooxygenase inhibitorRadiation therapySide effectsHealth problems
1998
Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Research 1998, 18: 2567-73. PMID: 9703911.Peer-Reviewed Original ResearchMeSH Keywords9,10-Dimethyl-1,2-benzanthraceneAnimalsAnticarcinogenic AgentsAntineoplastic AgentsCarcinoma, Lewis LungCell DivisionCholestanolsCisplatinCombined Modality TherapyCyclophosphamideDoxorubicinDrug Therapy, CombinationFemaleFluorouracilMammary Neoplasms, ExperimentalMiceOxygenOxygen ConsumptionPaclitaxelPartial PressureRatsRats, Inbred F344ConceptsLewis lung carcinomaTumor growth delayPost-tumor implantationLung carcinomaGrowth delayLung metastasesTumor implantationMammary carcinomaTumor oxygenationDay 4Chemotherapeutic agentsPrimary Lewis lung tumorMurine Lewis lung carcinomaDaily subcutaneous injectionsLewis lung tumorTumor-bearing animalsModest effectCombination therapyContinuous infusionCytotoxic therapySystemic diseaseSubcutaneous injectionLung tumorsAntiangiogenic agentsHypoxic fraction
1997
Reversal of in vivo drug resistance by the transforming growth factor‐β inhibitor decorin
Teicher B, Maehara Y, Kakeh Y, Ara G, Keyes S, Wong J, Herbst R. Reversal of in vivo drug resistance by the transforming growth factor‐β inhibitor decorin. International Journal Of Cancer 1997, 71: 49-58. PMID: 9096665, DOI: 10.1002/(sici)1097-0215(19970328)71:1<49::aid-ijc10>3.0.co;2-4.Peer-Reviewed Original ResearchConceptsEMT-6/CDDP tumorTumor cell survivalParent tumorResistant tumorsDrug resistanceAdministration of decorinCell survivalEMT-6/CTXPlasma TGF-beta levelsTGF-beta proteinGranulocyte-macrophage colony-stimulating factorSitu hybridizationTGF-beta levelsVivo drug resistanceHigher plasma levelsTGF-beta mRNATumor-bearing animalsMurine mammary tumorsGrowth factorColony-stimulating factorDrug responseDecorinCytotoxic therapyPlasma levelsTumor levelsProstate carcinoma response to cytotoxic therapy: in vivo resistance.
Teicher BA, Kakeji Y, Ara G, Herbst RS, Northey D. Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo 1997, 11: 453-61. PMID: 9509295.Peer-Reviewed Original ResearchConceptsPC-3 tumorsDU-145 tumorsTGF-beta mRNAPC-3 cellsDU-145 cellsLNCaP tumorsSingle dosesAndrogen-independent prostate cancerChemotherapy-resistant diseaseHuman prostate carcinoma cell linesConcentrations of melphalanIndependent prostate cancerProstate carcinoma cell linesProstate carcinoma xenograftsCytotoxic cancer therapyCell linesProstate cell linesVivo high levelsTime-dependent increaseChemotherapy administrationResistant diseaseCarcinoma cell linesCytotoxic therapyPlasma levelsCarcinoma response